HEALTH

P&G, GSK hold their own 
in crowded antacid aisle

BY Michael Johnsen

NEW YORK — Last year, the big question on every­one’s mind was: How many brands can actually thrive in what has become a cluttered antacid shelf? Because just exactly how many heartburn sufferers are there?


With some 65 million Americans affected by gastric complaints and 30% of those seriously affected with a major gastro event each year, the answer is enough to drive 13% growth into a category that was already above the $1-billion watermark across food, drug and mass (excluding Walmart), according to data provided by SymphonyIRI Group for the 52 weeks ended Oct. 3. That’s $150 million more than last year, and the annual indulgence of heartburn-
inducing holiday foods for the ensuing 2010 season hasn’t even begun. 


The lion’s share of that growth can be attributed to Novartis Consumer and its successful rollout of Prevacid 24HR, which generated $118 million within the first 11 months on shelf. And Merck Consumer brought in another $12.7 million with the launch of the third over-the-counter proton-pump inhibitor Zegerid OTC a little more than six months ago. 


But the real story may be in how both Procter & Gamble and GlaxoSmithKline Consumer Health successfully guarded — and in the case of GSK’s Tums, even grew — market share. 


Procter & Gamble only lost $11.9 million in annual sales (not including Walmart) of its clear market leader, Prilosec OTC. Not only did P&G have to contend with two new PPI competitors — Prevacid 24HR and Zegerid OTC — but the brand also had to compete for the second year with extensive store-brand-equivalent competition. According to Perrigo president, CEO and chairman Joe Papa, Perrigo’s omeprazole products brought in some $325 million through retail registers for the year through June 2010. 


GSK, meanwhile, grew sales by approximately 5.9% to $98.3 million across its top three Tums brands by stressing its fast-acting benefit; calcium relieves heartburn almost immediately, versus within an hour or so for such H2 blockers as Pepcid AC and Zantac, and a day or so for PPIs. “Tums is still a category driver with the highest household pen­etration and is a destination item in the category,” noted GSK Consumer director of sales Janet Carter-Smith. Immediate relief holds a 63% share of stomach, Carter-Smith added, with almost four times more buyers than PPIs and H2 blockers. 


But extended-relief and immediate-relief products address different needs for the consumer, Carter-Smith noted, and the needs of extended-relief 
products don’t necessarily cannibalize sales opportunities for immediate-
relief products, and vice versa. Extended-
relief and immediate-relief prod­ucts also serve different needs of the retailer; extended relief delivers a high dollar ring, while immediate relief helps contribute to trip opportunities. 


Partly for those reasons, GSK has positioned its Tums brand as a conjunctive sale to PPIs. “There are approximately 44 million PPI users with an estimated 81% experiencing breakthrough heartburn,” Carter-Smith said. “Tums doesn’t replace PPIs,” she said, but that immediate relief helps take care of that breakthrough heartburn on the spot.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

GE vet joins NBTY

BY Michael Johnsen

RONKONKOMA, N.Y. — NBTY on Monday named Jeffrey Nagel to the CEO post, succeeding Scott Rudolph, who will maintain his position as chairman.

Nagel comes to NBTY from General Electric, where he held senior leadership positions in several GE businesses addressing a variety of end markets, including oil and gas, consumer electronics, technology and aviation. He most recently served as head of GE Oil and Gas Global Services and was based in Florence, Italy.

In 2006, Nagel was made a GE corporate officer and appointed as the VP and general manager of GE Oil and Gas Global Services. Previously, he served as president and CEO of GE Inspection Technologies, general manager of business development in GE Aircraft Engines and president of GE Home Electric Products.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

DSE debuts new Anti Monkey Butt brand on Facebook

BY Michael Johnsen

EDISON, N.J. — DSE Healthcare Solutions on Sunday evening announced the launch of Safari Towels, a new product extending from its Anti Monkey Butt Powder brand, to its Facebook fan base of almost 39,000.

“Our new Safari Towels … so hot off the presses they aren’t even in stores yet!” the Anti Monkey Butt Powder status read. “Make a cool gift … from cyclists to soldiers, [they’re] great to have on hand for a ‘shower on the go.’ See them in our online store.”

The Safari Towels are premoistened, heavy-duty disposable towels that are large enough to clean an entire body surface without tearing. A Safari 6-pack (18 towels) are selling for $14.95 on the company’s website.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?